Clinical Trials Logo

Cancer of the Endometrium clinical trials

View clinical trials related to Cancer of the Endometrium.

Filter by:
  • Recruiting  
  • Page 1

NCT ID: NCT04080284 Recruiting - Endometrial Cancer Clinical Trials

Trial of Maintenance With Niraparib- Uterine Serous Carcinoma

Start date: December 30, 2019
Phase: Phase 2
Study type: Interventional

Uterine serous carcinoma (USC) accounts for up to 40% of endometrial cancer-related deaths. Patients with USC share many genomic and clinical characteristics with patients who has serous ovarian cancer. The objective of this study is to evaluate the efficacy of maintenance Niraparib regimen in patients with advanced or platinum sensitive recurrent uterine serous carcinoma. Additionally, the investigators aim to further describe the safety of this regimen. The investigators hypothesize that Niraparib maintenance will be a well-tolerated treatment and show significant response in patients with uterine serous carcinoma.

NCT ID: NCT03955978 Recruiting - Endometrial Cancer Clinical Trials

TSR-042 in Addition to Standard of Care Definitive Radiation for Inoperable Endometrial Cancer

Start date: October 15, 2019
Phase: Phase 1
Study type: Interventional

Patients with inoperable endometrial cancer have limited treatment options. PD-L1 expression is common in endometrial cancers and RT induces tumor and systemic changes that induce the immune system. The purpose of this trial is to evaluate anti-PD-1/PD-L1 axis therapy in conjunction of standard of care RT for patients with inoperable endometrial cancer in order to establish the safety and efficacy of inducing an anti-tumor immune response.

NCT ID: NCT03024398 Recruiting - Clinical trials for Cancer of the Endometrium

Evaluation of the Fluorescent Green of Indocyanine in the Detection of Sentinel Lymph Node in Endometrial Cancer

Sentimetre
Start date: January 1, 2017
Phase:
Study type: Observational

Selective lymphadenectomy Sentinel (LSS). This technique is already well established in breast cancer and melanoma and more recently in vulvar and cervical cancer. Compared to lymphadenectomy, it has several theoretical advantages: - this is a sensitive technique with a detection rate of> 90% and a false negative rate of <5%. - the anatomopathological techniques used (immunohistochemistry with anti-cytokeratin antibodies, serial sections) are more sensitive than the standard histological analysis of lymphadenectomy, which allows an improvement in the detection of metastases (micro-metastases, isolated tumor cells). In the SENTI-ENDO study, it was possible to detect lymph node metastases in 11% of patients with low-risk endometrial cancer and in 15% of intermediate-risk patients. - it avoids short-term and long-term operative and post-operative morbidity of lymphadenectomy. Early studies of LSS in endometrial cancer demonstrated superior efficacy of the colorimetric method coupled with the Technetium 99m isotopic method with an overall detection rate of 78% [95% CI: 73-84]. The fluorescent green of indocyanine appears to give better results with an overall detection rate of 94% and a bilateral detection rate of 80%. It seemed useful to take stock of this technique using this new dye.